<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The WL5 antibody is an anti-<z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> antibody secreted by the WL5 hybridoma clone </plain></SENT>
<SENT sid="1" pm="."><plain>Flow cytometric analysis showed that WL5 specifically binds to the HT29 and LS180 <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines </plain></SENT>
<SENT sid="2" pm="."><plain>Immunohistochemical analysis performed on a tissue microarray demonstrated that the WL5 antibody can be used for the specific and sensitive diagnosis of colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Furthermore, WL5 mediated antibody dependent cell-mediated cytotoxicity (ADCC) of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells and exhibited similar antitumor activity to adriamycin (ADM) but avoided the <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> and decrease in peripheral white blood cell counts associated with prolonged ADM treatment </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:chebi fb="2" ids="17089">glycoprotein</z:chebi>, carcinoembryonic antigen-related cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule 1 (CEACAM1), was identified as the target antigen of WL5 through immunoprecipitation and mass spectrometric analyses, which might provide a potential biomarker and therapeutic target for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>